Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

17.27
+0.66003.97%
Post-market: 16.90-0.3749-2.17%19:54 EDT
Volume:1.81M
Turnover:31.19M
Market Cap:945.51M
PE:-3.96
High:17.54
Open:16.95
Low:16.90
Close:16.61
Loading ...

Leerink Partners Keeps Their Buy Rating on uniQure (QURE)

TIPRANKS
·
05 Jun

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint

TIPRANKS
·
03 Jun

UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy

MT Newswires Live
·
02 Jun

uniQure provides regulatory update on AMT-130 for Huntington’s Disease

TIPRANKS
·
02 Jun

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
30 May

uniQure (QURE) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
30 May

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

uniQure presents case study of first patient dosed with AMT-260

TIPRANKS
·
29 May

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
12 May

RBC Capital Sticks to Their Buy Rating for uniQure (QURE)

TIPRANKS
·
12 May

Analysts Are Bullish on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), uniQure (QURE)

TIPRANKS
·
12 May

Stock Track | uniQure NV Soars 5.47% Pre-Market on Better-Than-Expected Q1 Results

Stock Track
·
09 May

Uniqure NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

uniQure Q1 EPS $(0.82) Beats $(0.95) Estimate, Sales $1.57M Miss $6.27M Estimate

Benzinga
·
09 May

uniQure recent selloff overdone, says H.C. Wainwright

TIPRANKS
·
09 May

Uniqure NV expected to post a loss of $1.01 a share - Earnings Preview

Reuters
·
07 May

uniQure to Announce First Quarter 2025 Financial Results

GlobeNewswire
·
06 May

Leerink Partners Remains a Buy on uniQure (QURE)

TIPRANKS
·
30 Apr

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

Zacks
·
29 Apr

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Apr